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Summary
Background: Previous studies show that statins
reduce total cholesterol (TC) concentration by both
21% in primary prevention (PP) and secondary
prevention (SP) in clinical trials and by 24% in
the general population. There are few data about
the efficacy of statins on TC concentration and
cardiovascular (CV) outcome in patients with
chronic kidney disease (CKD). We evaluated the re-
duction of TC concentration and subsequent risk of
CV morbidity and mortality with statins in CKD
patients.
Methods: A population-based cohort study using a
record-linkage database in Tayside, Scotland. A total
of 2369 patients who had a primary diagnosis of
CKD from Scottish Morbidity Record data or bio-
chemistry database (serum creatinine of 220mmol/l
or higher) and who had at least two separate TC
measurements between 1993 and 2007 were stu-
died. Patients were categorized into statin-exposed
and statin-unexposed groups according to statin use
status during the follow-up. They were also classi-
fied into PP (n=1325) and SP (n=1044) cohorts
at the entry date. The main outcomes were TC
concentration change from baseline, CV events
[Antiplatelet Trialist’s Collaboration (APTC)] and
all-cause mortality during the follow-up. Cox regres-
sion models, in which statin use was a time-
dependent variable, were employed to assess the
risk of outcome and adjusted for other known
confounders.
Results: Statin-associated TC concentrations decre-
ased by 0.59mmol/l (12%) in PP cohort and
0.56mmol/l (13%) in SP cohort from 4.77 and
4.48mmol/l at baselines, respectively. Statin use
was associated with a reduced risk of APTC
events, CV mortality or all-cause mortality in PP {ad-
justed hazard ratio (HR), 0.65 [95% confidence
interval (CI) 0.48–0.88]; 0.73 (95% CI 0.52–0.98);
0.59 (95% CI 0.48–0.73)} and SP [adjusted HR, 0.66
(95% CI 0.52–0.84); 0.60 (95% CI 0.47–0.77); 0.56
(95% CI 0.47–0.68)], respectively.
Conclusion: Statin use reduced TC concentrations
by 13% in patients with CKD. Statins were protect-
ive of APTC events, CV mortality and all-cause mor-
tality in patients with or without established CV
disease.
Introduction
Chronic kidney disease (CKD) is a worldwide public
health concern and it is estimated that 8.5% of the
population have stages 3–5 CKD in the UK.
1
Patients with any stage of CKD have an increased
risk of developing cardiovascular (CV) disease,
2–4
and are more likely to die from cardiovascular
disease (CVD) than to progress to end-stage kidney
failure.
5–8 Dyslipidemia occurs often in CKD pa-
tients and contributes to both CVD and worsening
renal function.
9 Statins reduce incident and recur-
rent CV events in trial population.
10 In trials of
CKD, statins reduced low density lipoprotein (LDL)
cholesterol by the same amount as in those
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11–13 Recently two meta-analyses of
randomized controlled trials (RCTs) indicated that
there was a reduction of recurrent CV events with
statin use in patients with any stage of CKD, and a
reduction in all-cause and CV mortality only in pa-
tients with less severe CKD.
11–12 The benefit of sta-
tins on the primary prevention (PP) of CV events was
not observed in a subgroup analysis with small
number CKD patients.
10 The main weakness of
these studies was the small-scale and short
follow-up.
Low density lipoprotein-C is rarely measurement
in clinical practice in the UK and doctors make
treatment decisions based on total cholesterol (TC)
plus or minus high density lipoprotein measure-
ments. We have shown that TC reductions with
lipid-lowering drugs were almost as good as low
density lipoprotein-C as a guide to therapy in the
statin trials
14 and that TC can be used with confi-
dence in the absence of low density lipoprotein-C.
15
In the present study, we investigated the impact of
statins on TC concentration and on the primary and
secondary prevention (SP) of Antiplatelet Trialist’s
Collaboration (APTC) events and all-cause mortality
in CKD patients in the setting of normal care.
Methods
We performed a cohort study in Tayside, Scotland
using the Medicines Monitoring (MEMO) Unit
record-linked database. The MEMO database
covers a geographically compact population and
serves about 400000 patients in the National
Health Service (NHS) in Tayside, Scotland. It has
all-dispensed prescription data in the Tayside com-
munity from 1989 onward. The data collection
methods have previously been described.
16 In
brief, MEMO contains several data sets including
all dispensed community prescriptions, hospital dis-
charge data, biochemistry data and other data; these
data are linked by a unique patient identifier, the
community health index number. Data are anon-
ymized for the purposes of research as approved
by the Caldicott Guardians. This project was also
approved by the Tayside Committee on Research
Medical Ethics.
Study population
The study population consisted of residents of
Tayside who were registered with a general practi-
tioner between January 1993 and December 2007
and remained resident in Tayside or died during the
study period.
Study subjects
Study subjects were those with a primary diagnosis
of CKD between January 1993 and December 2007.
They were identified from the following databases:
Scottish Morbidity Record 1 (SMR01) data coded
either as 585 or 403 according to the 9th revision
of International Classification of Disease (ICD9) or
N18 according to the 10th revision (ICD10)
17 and
regional biochemistry database (serum creatinine of
5220mmol/l). The date of the first diagnosis of CKD
was used as the entry date. These subjects had at
least two TC measurements within a minimum time
interval of 30 days during the follow-up. They were
categorized into statin-exposed and statin-
unexposed groups according to whether or not
they were taking statin treatment during the
follow-up. Patients who used statins prior to the
study entry were excluded from the study. Subjects
who were prescribed other lipid-lowering drugs after
the entry date or within 180 days prior to the entry
date were excluded. The cohort was also classified
into PP and SP cohorts in the analysis according to
whether they had established CVD [stroke, transient
ischemic attack (TIA), myocardial infarction (MI),
angina and heart failure (HF)] prior to the entry date.
TC measurements
Serum TC measurements were obtained from the
regional biochemistry database. Baseline TC con-
centration was the concentration measured on the
nearest date to the entry date. This date was in the
range of within 1 year before or within 30 days after
the entry date. Follow-up TC concentration met the
following criteria: (i) on or within 180 days prior to
the incident or recurrent CV admission; (ii) the last
available TC measurement during follow-up in pa-
tients without CV admission; and (iii) at least 30 days
after the statin treatment in the statin-exposed group.
Outcome variables
The primary study outcome was TC concentration
change from baseline, and the secondary outcomes
were incident or recurrent APTC events and
all-cause mortality during the follow-up. We used
the APTC end point of non-fatal MI (ICD9: 410;
ICD10: I21), non-fatal stroke (ICD9: 431, 434.9,
436; ICD10: I61, I63, I64) or CV death (ICD9:
390–459; ICD10: I00–I99) as the primary CV end
points. They were ascertained from SMR01 data ac-
cording to the ICD9 or ICD10 codes and occurred at
least 30 days after statin treatment in the
statin-exposed group or after the entry date in the
statin-unexposed group. All-cause mortality data
were obtained from the General Register Office for
642 X. Sheng et al.Scotland. Same criteria to TC measurement for CV
outcome were applied to the all-cause mortality
outcome.
Covariates
The covariates were consisted of patient character-
istics (age at entry to the study, gender, socioeco-
nomic status and TC concentration at baseline), use
of medications at baseline including analgesics, cor-
ticosteroids, non-steroidal anti-inflammatory drugs
(NSAIDs) and CV drugs of positive inotropic
drugs, diuretics, antiarrhythmic drugs, b-adrenocep-
tor blocking drugs, drugs used in hypertension
and HF, nitrates, calcium-channel blockers and
other antianginal drugs, anticoagulants, antiplatelet
drugs, comorbidities of diabetes mellitus, angina,
TIA or HF. The Scottish Index of Multiple
Deprivation (SIMD) was used as a measure of socio-
economic status.
18
Statistical analysis
Data were summarized as mean (SD) for continuous
variables and numbers of subjects (percentage) for
categorical variables. To examine differences in
baseline characteristics between the groups, 
2
and t-tests were performed. TC concentration
changes were calculated as baseline TC concentra-
tion minus follow-up TC concentration. In the statin
group, patients started statin treatment at different
times during the follow-up period. Therefore, the
time between the date of study entry and the date
of first statin prescription is immortal. To control this
immortal time bias, a Cox regression model with a
time-dependent variable of statin treatment was
constructed to analyze the time to CV admission
and separately for all-cause mortality and adjusted
for potential confounders. Data were expressed as
hazard ratios (HRs) with 95% confidence intervals
(CIs). The Cox model assumptions were checked
before the analysis. Sensitivity analyzes were per-
formed in patients who had at least two high density
lipoprotein-C concentration measurements. All
analyses were carried out using SAS version 9.1.
All P-values were two-sided.
Results
PP
Figure 1 shows a flowchart of the patients in the
study. The PP cohort consisted of 1325 CKD pa-
tients (740 in the statin-exposed group and 585 in
the statin-unexposed group). Patients in the
statin-exposed group were more likely to be
younger, taking medications of analgesics, cortico-
steroids and CV drugs, and had more diabetes than
those in the statin-unexposed group (Table 1).
Statin-associated TC concentration fell by
0.59mmol/l (95% CI 0.48–0.70) (12%) from the
baseline of 4.77mmol/l (SD 1.38) to follow-up of
4.18mmol/l (SD 1.17) (Figure 2a). TC concentration
also fell by 3% in the statin-unexposed group.
Statins had a similar effect on TC concentration re-
duction regardless of male or female patients
(Figure 2a).
There were 99 CV events in the statin-exposed
group and 109 in the statin-unexposed group
during the 2301 and 1408 person-years (PYs)
follow-up, with the crude incidence of APTC events
per 100 PYs of 4.30 (95% CI 3.53–5.24) and 7.75
(95% CI 6.43–9.33), respectively (Table 3). There
were 34 non-fatal MI, 18 non-fatal stroke, 71 CV
deaths and 165 all-cause deaths in the statin-treated
groups and 34, 22, 98 and 269 in statin-unexposed
groups. The crude event rate for each component of
APTCandthecrudemortalityrateintwogroupswere
shown in Table 3.
Compared with the statin-unexposed group, statin
treatment reduced risk of CV events [adjusted HR,
0.65 (95% CI 0.48–0.88)] (Figure 3). Patients who
were older, use of positive inotropic drugs, with hos-
pital admission of angina, TIA or HF had an
increased risk of CVD. However, patients who
were more affluent, or used analgesics, corticoster-
oids and NSAIDs carried a lower risk of CVD
(Table 2). An effect of statins on CV mortality was
observed [adjusted HR, 0.73 (95% CI 0.52–0.98],
but not on non-fatal MI or non-fatal stroke
(Figure 3). Statin use was associated with 41% re-
duction in all-cause mortality [adjusted HR, 0.59
(95% CI 0.48–0.73)].
SP
A total of 1044 patients (686 statin-exposed and 358
statin-unexposed) with established CVD were
included in this cohort. Patients in the statin-
exposed group were younger, had more diabetes,
used more analgesics and corticosteroids and more
some CVD drugs (Table 1). Figure 2b shows that
there was 13% TC reduction (0.56mmol/l 95% CI
0.46–0.67) with statin therapy from baseline TC of
4.48mmol/l (SD 1.35). There was also an 8% TC
reduction observed over time in the statin-
unexposed group. Comparable TC changes in
male and female were observed in two groups
(Figure 2b).
Recurrent CV events occurred in 208
statin-exposed patients and in 157 statin-unexposed
patients during 1822 and 640 PYs follow-up time
Effectiveness of statins in CKD 643with crude event rates of 11.42 (95% CI 9.97–13.08)
per 100 PYs and 24.88 (95% CI 21.31–29.05) per
100 PYs, respectively (Table 3). For the individual
APTC components, there were 55 non-fatal MI, 33
non-fatal stroke and 148 CV deaths. There were also
244 all-cause deaths in the statin-exposed group.
Correspondingly, 38, 23, 161 and 259 events
occurred in the statin-unexposed group. The crude
event rates per 100 PYs for each outcome were
described in Table 3.
A significant risk reduction of 34% in recurrent
CV events [adjusted HR, 0.66 (95% CI 0.52–
0.84)], 45% in non-fatal MI, 58% in non-fatal
stroke, 40% in CV mortality were observed in the
statin-exposed group (Figure 3). Older patients and
patients with prior hospitalizations of angina, TIA or
HF had an increased risk of CVD. In contrast, use of
analgesics, b-adrenoceptor blocking drugs, drugs
used in hypertension and HF, antiplatelet drugs, cor-
ticosteroids and NSAIDs had a reduced risk of CVD
(Table 2). The risk of all-cause mortality was
reduced by 44% with statin use [adjusted HR,
0.56 (95% CI 0.47–0.68)].
Sensitivity analysis
In patients who had high density lipoprotein-C meas-
urementsavailable(PP:696inthestatin-exposedand
505 in the statin-unexposed group; SP: 610 and 282,
respectively) both high density lipoprotein-C
Patients with a primary diagnosis of CKD from 
1993 and 2007 
(n=12,754)
Patients with statin-unexposed
(n=9,994)
Patients with statin-exposed
(n=2,760)
SP cohort
(n=686)
SP cohort
(n=358)
Patients with statin-
unexposed
(n=1,055)
Patients with statin-
exposed
(n=1,619)
PP cohort
(n=585)
PP cohort
(n=740)
Subjects with at least two separate TC measurements. 
Baseline TC was in the range of within one year
before or within 30 days after the entry date. Follow -
up TC met the following criteria: (1) on or within 180 
days prior to the CV admission; (2) the last available 
TC measurement during follow -up in patients 
without the CV admission; (3) at least 30 days after 
statin use in the statin-exposed group.
Excluding subjects with other lipid -lowering drugs 
after the entry date or within 180 days prior to the 
entry date (n=141).
Excluding subjects with cancer diagnosis (n=122) .
Excluding Patients moving out the Tayside during 
the follow-up (n=42).
Figure 1. Flowchart for identification of patients in the statin-exposed and statin-unexposed cohorts.
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1.34mmol/l (SD 0.46) in the PP and by 5% from
1.27mmol/l (SD 0.43) in the SP at the baselines.
Statins had a comparable impact on CV events [PP:
0.61 (95% CI 0.45–0.84); SP: 0.59 (95% CI 0.46–
0.78)] and all-cause mortality [PP: 0.62 (95% CI
0.50–0.79); SP: 0.55 (95% CI 0.44–0.68)] in patients
with high density lipoprotein-C measurement.
Meanwhile, a risk reduction of non-fatal MI,
non-fatal stroke or CV mortality in patients with
prior CV admission was consistent and the HRs
were similar to the main results. High density
lipoprotein-C could be used to guide statin use as
well as TC in the absence of LDL-C measurements
in patients with CKD.
Discussion
To our knowledge, this is the first population-based
study to study the impact of statins on TC concen-
tration and CV outcome among CKD patients in
normal clinical care setting. Use of statins was asso-
ciated with risk reductions of APTC events (non-fatal
MI, non-fatal stroke or CV death), CV mortality and
all-cause mortality in both PP and SP of CVD. Risk
reductions of non-fatal MI and non-fatal stroke were
observed in patients with prior CVD. These findings
were robust when sensitivity analyzes were per-
formed by taking HDL-C into the consideration or
by excluding prevalent statin-exposed patients.
Compared with TC lowering with lipid-lowering
drugs in the general population that excluded
CKD patients (24% reduction)
14 or TC reduction
in the PP and SP of statin trials (both of 21% re-
duction),
15 statin-associated TC reductions were
smaller in patients with CKD than the general
population. A lower baseline TC concentration in
CKD patients than that in the general population
appeared to be related to a lower TC reduction
with statin therapy.
Three meta-analyzes have been done recently.
Strippoli et al.
11 analyzed 50 RCTs and found that
TC concentration was significantly lower by 19%
Table 1 Baseline characteristics of subjects in the PP and SP of CVD
Baseline characteristics PP SP
Statin-
exposed
n (%)
Statin-
unexposed
n (%)
P value Statin-
exposed
n (%)
Statin-
unexposed
n (%)
P-value
Number of subjects 740 585 – 686 358 –
Age
a 67.7 (13.5) 70.2 (15.6) <0.001 73.4 (10.1) 77.2 (9.6) <0.01
Male 387 (52.7) 315 (54.7) 0.50 411 (60.4) 224 (62.8) 0.45
Baseline TC concentration (mmol/l)
a 4.77 (1.38) 4.67 (1.20) 0.17 4.48 (1.35) 4.68 (1.32) 0.203
Social economic status
1 (most deprived) 172 (24.1) 150 (26.7) 0.76 201 (30.3) 116 (33.2) 0.47
2 167 (23.4) 125 (22.2) 148 (22.3) 82 (23.5)
3 147 (20.6) 106 (12.9) 111 (16.7) 63 (18.1)
4 108 (15.1) 92 (16.4) 100 (15.1) 46 (13.2)
5 (most affluent) 121 (16.9) 89 (15.8) 104 (15.7) 42 (12.0)
Concurrent use of drugs
Analgesics 510 (68.9) 358 (61.2) <0.01 504 (73.5) 217 (60.6) <0.01
Positive inotropic drugs 60 (8.1) 67 (11.5) 0.03 146 (21.3) 99 (27.7) 0.02
Diuretics 543 (73.4) 345 (58.9) <0.01 566 (82.5) 281 (78.5) 0.12
Antiarrhythmic drugs 15 (2.0) 13 (2.2) 0.84 48 (7.0) 31 (8.7) 0.34
b-Adrenoceptor blocking drugs 341 (46.1) 172 (29.4) <0.01 389 (56.7) 113 (31.4) <0.01
Hypertension and HF 527 (71.2) 261 (44.6) <0.01 495 (72.2) 185 (51.7) <0.01
Nitrates and calcium-channel blockers 524 (70.8) 284 (48.6) <0.01 546 (79.6) 219 (61.2) <0.01
Anticoagulants 99 (13.4) 80 (13.7) 0.83 166 (24.2) 80 (22.4) 0.50
Antiplatelet drugs 433 (58.5) 207 (35.4) <0.001 535 (78.0) 221 (61.7) <0.01
Corticosteroids 248 (33.5) 156 (26.7) <0.001 235 (34.3) 84 (23.5) <0.01
NSAIDs 144 (19.5) 110 (18.8) 0.71 132 (19.2) 58 (16.3) 0.23
Comorbidity
Diabetes mellitus 231 (31.2) 115 (19.7) <0.01 209 (30.5) 85 (23.7) 0.02
Angina, TIA and HF 61 (8.2) 38 (6.4) 0.62 239 (34.8) 116 (32.4) 0.44
aData expressed as mean (SD).
Effectiveness of statins in CKD 645with statins than with placebo in CKD patients with
established CVD. This is numerically larger than our
TC reduction in SP (13%). Also, statin treatment
reduced the risk of recurrent CV events [relative
risk (RR) 0.78 (95% CI 0.73–0.84)] and CV mortality
[RR 0.81 (95% CI 0.73–0.90)], but not in all-cause
mortality [RR 0.92 (95% CI 0.82–1.03)]. Other two
systematic reviews of RCT reported that statins
decreased lipid levels in CKD patients requiring dia-
lysis (27%) and not requiring dialysis
(23%)
12–13and these reductions were larger than
in our study. Statin use was associated with major
mortality benefits [all-cause mortality: RR 0.81 (95%
CI 0.74–0.89); CV deaths: RR 0.80 (95% CI 0.70–
0.90)] in CKD patients not requiring dialysis,
12 but
not in dialysis patients [all-cause mortality: RR 0.95
(95% CI 0.86–1.06); CV mortality: RR 0.96 (95% CI
0.65–1.40)].
13 The benefit of statins in improving
non-fatal CV events was observed in CKD patients
not requiring dialysis [RR 0.75 (95% CI 0.66–
0.85)]
12 and with hemodialysis [RR 0.86 (95% CI
0.74–0.99)].
13 But some potential limitations were
that all these results were dominated by the results
of one large study and there were small number of
events in many studies. In general, the effect of sta-
tins in CKD patients in these trials was similar to that
seen in our study.
The major strength of our study is that it was
population based with a long follow-up (15 years)
and included CKD patients with and without prior
CVD. Also the accurate biochemical data of dysli-
pidemia was taken into account. It is possible that
other unmeasured confounders might have influ-
enced the results of our analysis. We used serum
creatinine rather than estimated glomerular filtration
rate that is a better measurement for renal function
to identify patients in the study. We did not consider
types of statins, statin dose titration, effects of life-
styles and others in our study.
In summary, our study results show that the per-
centage reduction of TC with statins in CKD is less
than the general population. However, statins were
associated with reduced risk of incident or recurrent
CV events (non-fatal MI, non-fatal stroke or CV
death) and improve all-cause mortality in patients
with or without established CVD.
Conflict of interest: None declared.
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Figure 2. TC concentration changes in the (a) PP and (b) SP of CVD.
646 X. Sheng et al.Table 2 Univariate and multivariate analyzes in the PP and SP of CVD
Outcome predictor PP SP
Unadjusted HR Adjusted HR Unadjusted HR Adjusted HR
Statins 0.57 (0.43–0.75) 0.65 (0.48–0.88) 0.47 (0.38–0.58) 0.66 (0.52–0.84)
Age 1.05 (1.03–1.06) 1.04 (1.03–1.06) 1.03 (1.02–1.04) 1.02 (1.00–1.03)
Male/female 1.06 (0.81–1.40) 1.14 (0.85–1.53) 0.83 (0.67–1.02) 0.89 (0.71–1.12)
Baseline TC concentration (mmol/l) 0.99 (0.89–1.10) 1.08 (0.96–1.21) 1.00 (0.94–1.08) 1.00 (0.92–1.08)
Social economic status
1 (most deprived) 1.00 1.00 1.00 1.00
2–3 0.63 (0.45–0.87) 0.54 (0.38–0.75) 1.08 (0.85–1.37) 0.96 (0.75–1.22)
4–5 (most affluent) 0.78 (0.55–1.08) 0.62 (0.44–0.88) 0.85 (0.65–1.11) 0.78 (0.59–1.02)
Concurrent use of drugs
Analgesics 0.64 (0.48–0.85) 0.69 (0.50–0.94) 0.49 (0.40–0.61) 0.50 (0.40–0.63)
Positive inotropic drugs 1.94 (1.33–2.83) 1.71 (1.11–2.61) 1.28 (1.03–1.60) 0.99 (0.77–1.29)
Diuretics 0.95 (0.70–1.27) 0.86 (0.61–1.21) 0.96 (0.72–1.27) 1.10 (0.81–1.49)
Antiarrhythmic drugs 1.11 (0.46–2.69) 0.71 (0.29–1.78) 0.80 (0.54–1.19) 0.70 (0.47–1.05)
b-Adrenoceptor blocking drugs 0.79 (0.60–1.05) 0.78 (0.58–1.05) 0.51 (0.41–0.63) 0.59 (0.47–0.75)
Hypertension and HF 0.67 (0.51–0.88) 0.82 (0.60–1.21) 0.55 (0.44–0.68) 0.70 (0.55–0.88)
Nitrates and calcium-channel blockers 0.85 (0.64–1.13) 1.03 (0.75–1.41) 0.62 (0.49–0.79) 0.95 (0.73–1.23)
Anticoagulants 1.14 (0.79–1.64) 1.01 (0.67–1.53) 0.94 (0.74–1.19) 0.82 (0.61–1.10)
Antiplatelet drugs 1.29 (0.97–1.70) 1.24 (0.91–1.68) 0.64 (0.51–0.80) 0.74 (0.56–0.98)
Corticosteroids 0.51 (0.37–0.70) 0.68 (0.49–0.95) 0.65 (0.52–0.83) 0.77 (0.60–0.98)
NSAIDs 0.50 (0.34–0.73) 0.52 (0.35–0.77) 0.57 (0.43–0.75) 0.67 (0.51–0.89)
Comorbidity
Diabetes mellitus 0.80 (0.58–1.11) 0.86 (0.61–1.21) 0.97 (0.77–1.21) 1.04 (0.82–1.31)
Angina, TIA and HF 2.36 (1.65–3.39) 2.45 (1.68–3.58) 1.45 (1.18–1.78) 1.96 (1.56–2.46)
Primary Prevention 
.2 .5 1 2 .2 .5 1
Adjusted 0.59 (0.48, 0.73)
Unadjusted 0.44 (0.36, 0.53)
All-cause mortality
Adjusted 0.73 (0.52, 0.98)
Unadjusted 0.48 (0.36, 0.66)
CV death
Adjusted 0.55 (0.28, 1.09)
Unadjusted 0.48 (0.26, 0.88)
Non-fatal stroke
Adjusted 0.71 (0.38, 1.32)
Unadjusted 0.65 (0.40, 1.04)
Non-fatal MI
Adjusted 0.65 (0.48, 0.88)
Unadjusted 0.57 (0.43, 0.75)
APTC events
Hazards Ratio (95%CI)
Secondary Prevention 
0.56 (0.47, 0.68) Adjusted
0.40 (0.33, 0.47) Unadjusted
All-cause mortality
0.60 (0.47, 0.77) Adjusted
0.39 (0.31, 0.48) Unadjusted
CV death
0.42 (0.20, 0.91) Adjusted
0.52 (0.30, 0.88) Unadjusted
Non-fatal stroke
0.55 (0.32, 0.95) Adjusted
0.51 (0.34, 0.78) Unadjusted
Non-fatal MI
0.66 (0.52, 0.84) Adjusted
0.47 (0.38, 0.58) Unadjusted
APTC events
Hazards Ratio (95%CI)
Figure 3. Unadjusted and adjusted hazards ratios of APTC events and mortality associated with statins.
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